Angiogenesis in inflammatory joint disease: a target for therapeutic intervention.
作者信息
Brenchley P E
出版信息
Clin Exp Immunol. 2000 Sep;121(3):426-9. doi: 10.1046/j.1365-2249.2000.01299.x.
Abstract
摘要
相似文献
1
Angiogenesis in inflammatory joint disease: a target for therapeutic intervention.
Clin Exp Immunol. 2000 Sep;121(3):426-9. doi: 10.1046/j.1365-2249.2000.01299.x.
2
Vascular endothelial growth factor: molecular and biological aspects.
Curr Top Microbiol Immunol. 1999;237:1-30. doi: 10.1007/978-3-642-59953-8_1.
3
[Angiogenesis update].
Bull Cancer. 1999 Jan;86(1):29-36.
4
The role of angiogenic growth factors in breast cancer progression.
Cancer Metastasis Rev. 1996 Jun;15(2):213-9. doi: 10.1007/BF00437474.
5
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
Cancer J Sci Am. 1998 Jul-Aug;4(4):209-17.
6
[Vascular endothelial growth factor VEGF stimulates angiogenesis in good and bad situations].
Dtsch Med Wochenschr. 1998 Feb 27;123(9):259-65. doi: 10.1055/s-2007-1023947.
7
Vascular endothelial growth factor. The trigger for neovascularization in the eye.
Lab Invest. 1995 Jun;72(6):615-8.
8
[The role of angiogenesis in rheumatoid arthritis].
Postepy Hig Med Dosw. 2000;54(6):855-65.
9
[Role of receptor tyrosine kinase in the angiogenesis].
Hautarzt. 2002 Sep;53(9):629-42. doi: 10.1007/s00105-002-0425-x.
10
[Tumoral angiogenesis: physiopathology, prognostic value and therapeutic perspectives].
Rev Med Interne. 1998 Dec;19(12):904-13. doi: 10.1016/s0248-8663(99)80063-0.
引用本文的文献
1
Vascular endothelial growth factor A inhibition remodels the transcriptional signature of lipid metabolism in psoriasis non-lesional skin in 12 h ex vivo culture.
Skin Health Dis. 2024 Oct 26;4(6):e471. doi: 10.1002/ski2.471. eCollection 2024 Dec.
2
Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Front Immunol. 2021 May 27;12:674343. doi: 10.3389/fimmu.2021.674343. eCollection 2021.
3
Intervening upregulated SLC7A5 could mitigate inflammatory mediator by mTOR-P70S6K signal in rheumatoid arthritis synoviocytes.
Arthritis Res Ther. 2020 Aug 31;22(1):200. doi: 10.1186/s13075-020-02296-8.
4
The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.
Clin Exp Immunol. 2016 Apr;184(1):62-72. doi: 10.1111/cei.12758. Epub 2016 Jan 19.
5
Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.
DNA Cell Biol. 2014 Apr;33(4):234-44. doi: 10.1089/dna.2013.2252.
6
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.
Clin Cosmet Investig Dermatol. 2013 Sep 26;6:233-44. doi: 10.2147/CCID.S35312.
7
Increase levels of apo-A1 and apo B are associated in knee osteoarthritis: lack of association with VEGF-460 T/C and +405 C/G polymorphisms.
Rheumatol Int. 2008 Nov;29(1):63-8. doi: 10.1007/s00296-008-0633-5. Epub 2008 Jul 3.
8
Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients.
Clin Rheumatol. 2007 Dec;26(12):2023-2029. doi: 10.1007/s10067-007-0605-2. Epub 2007 Mar 29.
9
Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky.
Arthritis Res Ther. 2004;6(2):60-72. doi: 10.1186/ar1156. Epub 2004 Mar 8.
10
Angiogenesis as a target in rheumatoid arthritis.
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii60-7. doi: 10.1136/ard.62.suppl_2.ii60.
本文引用的文献
1
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production.
Cytokine. 2000 Aug;12(8):1232-5. doi: 10.1006/cyto.2000.0692.
2
Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid.
Clin Exp Immunol. 2000 Jan;119(1):182-8. doi: 10.1046/j.1365-2249.2000.01097.x.
3
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Nat Med. 1999 Dec;5(12):1418-23. doi: 10.1038/70995.
4
Clinical applications of angiogenic growth factors and their inhibitors.
Nat Med. 1999 Dec;5(12):1359-64. doi: 10.1038/70928.
5
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid.
Clin Exp Immunol. 1999 Jul;117(1):171-6. doi: 10.1046/j.1365-2249.1999.00949.x.
6
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis.
Nat Med. 1999 Jul;5(7):793-802. doi: 10.1038/10518.
7
Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells.
Clin Exp Immunol. 1999 May;116(2):360-5. doi: 10.1046/j.1365-2249.1999.00876.x.
8
Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis.
Rheumatology (Oxford). 1999 Jan;38(1):34-42. doi: 10.1093/rheumatology/38.1.34.
9
Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts.
Clin Exp Immunol. 1999 Jan;115(1):176-82. doi: 10.1046/j.1365-2249.1999.00775.x.
10
Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.
J Clin Invest. 1999 Jan;103(1):47-54. doi: 10.1172/JCI3756.
Zotero 插件